Multiomic single-cell studies are revolutionizing knowledge of the tumor immune microenvironment and are uniquely positioned to detect rare cell subsets that correlate in response to immunotherapy. DNA-barcoded antibody panels enable unambiguous classification of cell subsets via simultaneous measurement of surface proteins and the transcriptome. However, single-cell sequencing performs best on fresh samples while multicenter clinical trials routinely obtain frozen specimens.
In this on-demand webinar, Jasmine Chen, director of genomics at Abiosciences, shares Abiosciences’ effort in evaluating BioLegend’s TotalSeq-C Human Universal Cocktail using the 10x Genomics single-cell platform on fresh and frozen PBMCs. This includes bioinformatics pipelines to compare the quality control metrics, isotype-matched control performance, and cell subtype analyses. Advanced visualization and analysis tools were developed to interrogate the data in a flow cytometry paradigm, including complex gating strategies to identify rare cell subtypes. The pilot study is being expanded to larger-scale clinical settings and may help characterize important cell populations that are associated with disease status, pharmacodynamics, and therapeutic response.
Offered Free by: BioLegend
See All Resources from: BioLegend